A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s DiseaseFarlow M. · Anand R. · Messina Jr J. · Hartman R. · Veach J.
aDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Ind., and bDepartments of Medical Affairs CNS and Statistics, Novartis Pharmaceuticals Corporation, East Hanover, N.J., USA
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer’s disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6–12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.
Copyright © 2000 S. Karger AG, Basel
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50